Trials / Completed
CompletedNCT01362504
Pro-adrenomedullin as a Prognostic Marker in Neonatal Sepsis
Zekai Tahir Burak Maternity Teaching Hospital Neonatal Intensive Care Unit
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (estimated)
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital · Academic / Other
- Sex
- All
- Age
- 24 Weeks – 42 Weeks
- Healthy volunteers
- Accepted
Summary
The aim of this study was to clarify the prognostic value of serum pro-Adrenomedullin level in neonatal sepsis. Eighty term and preterm neonates with sepsis were enrolled in this study. Eighty healthy matched neonates served as a control group.
Conditions
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2011-08-01
- Completion
- 2011-09-01
- First posted
- 2011-05-30
- Last updated
- 2011-10-12
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01362504. Inclusion in this directory is not an endorsement.